Top

Current Cardiology Reports

Published in:

Open Access 16-11-2023 | Heart Failure | Heart Failure (HJ Eisen, Section Editor)

Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

Authors: Johannes-Paul Fladerer, Selina Grollitsch

Published in: Current Cardiology Reports | Issue 12/2023

Abstract

Purpose of Review

According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Heart failure has been defined as a global pandemic leading to millions of deaths. Recent research clearly approved the beneficial effect of Coenzyme Q10 supplementation in treatment and prevention of cardiovascular disease in patients with heart failure in clinical trials but did not distinguish between the oxidised form CoQ10 and reduced form CoQH2 of Coenzyme Q10. The aim of this study is to determine differences in medical application of CoQ10 and CoQH2 supplementation and evaluate the efficacy of CoQ10 and CoQH2 supplementation to prevent cardiovascular disease in patients with heart failure.

Recent Findings

A PubMed search for the terms “ubiquinone” and “ubiquinol” was conducted, and 28 clinical trials were included. Our findings go along with the biochemical description of CoQ10 and CoQH2, recording cardiovascular benefits for CoQ10 and antioxidative and anti-inflammatory properties for CoQH2. Our main outcomes are the following: (I) CoQ10 supplementation reduced cardiovascular death in patients with heart failure. This is not reported for CoQH2. (II) Test concentrations leading to cardiovascular benefits are much lower in CoQ10 studies than in CoQH2 studies. (III) Positive long-term effects reducing cardiovascular mortality are only observed in CoQ10 studies.

Summary

Based on the existing literature, the authors recommend CoQ10 instead of CoQH2 to treat and prevent cardiovascular disease in patients with heart failure.

World Health Organization. Global action plan for the prevention and control of NCDs 2013–2020 // Global action plan for the prevention and control of noncommunicable diseases, 2013–2020. Geneva, Switzerland: World Health Organization; 2013.

Global Health Metrics. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7.CrossRef

Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272–87. https://doi.org/10.1093/cvr/cvac013.CrossRefPubMed

Sue-Ling CB, Abel WM, Sue-Ling K. Coenzyme Q10 as adjunctive therapy for cardiovascular disease and hypertension: a systematic review. J Nutr. 2022;152:1666–74. https://doi.org/10.1093/jn/nxac079.CrossRefPubMed

Linnane AW, Kios M, Vitetta L. Coenzyme Q(10)–its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion. 2007;7(Suppl):S51-61. https://doi.org/10.1016/j.mito.2007.03.005.CrossRefPubMed

Mantle D, Dybring A. Bioavailability of Coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants (Basel) 2020;9. https://doi.org/10.3390/antiox9050386.

Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20:591–8. https://doi.org/10.1080/07315724.2001.10719063.CrossRefPubMed

Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:31–7. https://doi.org/10.1007/s12033-007-0052-y.CrossRefPubMed

Yubero-Serrano EM, Gonzalez-Guardia L, Rangel-Zuñiga O, et al. Mediterranean diet supplemented with coenzyme Q10 modifies the expression of proinflammatory and endoplasmic reticulum stress-related genes in elderly men and women. J Gerontol A Biol Sci Med Sci. 2012;67:3–10. https://doi.org/10.1093/gerona/glr167.CrossRefPubMed

10.

• Judy WV. The instability of the lipid-soluble antioxidant ubiquinol: part 3–misleading marketing claims. Integr Med (Encinitas). 2021;20:24–8. Important critical review outlining limitations of different studies concerning CoQH2.PubMed

11.

Judy WV. The instability of the lipid-soluble antioxidant ubiquinol: part 2-dog studies. Integr Med (Encinitas). 2021;20:26–30.PubMed

12.

Judy WV. The instability of the lipid-soluble antioxidant ubiquinol: part 1-lab studies. Integr Med (Encinitas). 2021;20:24–8.PubMed

13.

López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019;57:133–40. https://doi.org/10.1016/j.nut.2018.05.020.CrossRefPubMed

14.

Raizner AE, Quiñones MA. Coenzyme Q10 for patients with cardiovascular disease: JACC focus seminar. J Am Coll Cardiol. 2021;77:609–19. https://doi.org/10.1016/j.jacc.2020.12.009.CrossRefPubMed

15.

Gutierrez-Mariscal FM, La Cruz-Ares S de, Torres-Peña JD et al. Coenzyme Q10 and cardiovascular diseases. Antioxidants (Basel) 2021;10. https://doi.org/10.3390/antiox10060906.

16.

Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig. 1993;71:S155–61. https://doi.org/10.1007/BF00226859.CrossRefPubMed

17.

Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71:S134–6. https://doi.org/10.1007/BF00226854.CrossRefPubMed

18.

Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg. 1994;58:1427–32. https://doi.org/10.1016/0003-4975(94)91928-3.CrossRefPubMed

19.

Morisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol Aspects Med. 1994;15(Suppl):s155–63. https://doi.org/10.1016/0098-2997(94)90025-6.CrossRefPubMed

20.

Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347–53. https://doi.org/10.1023/a:1007764616025.CrossRefPubMed

21.

Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27:295–9. https://doi.org/10.1002/clc.4960270512.CrossRefPubMed

22.

Chew GT, Watts GF, Davis TME, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care. 2008;31:1502–9. https://doi.org/10.2337/dc08-0118.CrossRefPubMedPubMedCentral

23.

Makhija N, Sendasgupta C, Kiran U, et al. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2008;22:832–9. https://doi.org/10.1053/j.jvca.2008.03.007.CrossRefPubMed

24.

Kuimov AD, Murzina TA. Coenzyme q10 in complex therapy of patients with ischemic heart disease. Kardiologiia. 2013;53:40–3.PubMed

25.

•• Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2:641–9. https://doi.org/10.1016/j.jchf.2014.06.008. Proving that CoQ10 decreases mortality in patients with heart failure.CrossRefPubMed

26.

Aslanabadi N, Safaie N, Asgharzadeh Y, et al. The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention. Cardiovasc Ther. 2016;34:254–60. https://doi.org/10.1111/1755-5922.12195.CrossRefPubMed

27.

Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiol J. 2019;26:147–56. https://doi.org/10.5603/CJ.a2019.0022.CrossRefPubMedPubMedCentral

28.

Sobirin MA, Herry Y, Sofia SN, et al. Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discov Ther. 2019;13:38–46. https://doi.org/10.5582/ddt.2019.01004.CrossRefPubMed

29.

Khan A, Johnson DK, Carlson S, et al. NT-Pro BNP predicts myocardial injury post-vascular surgery and is reduced with CoQ10: a randomized double-blind trial. Ann Vasc Surg. 2020;64:292–302. https://doi.org/10.1016/j.avsg.2019.09.017.CrossRefPubMed

30.

Kuklinski B, Weissenbacher E, Fähnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med. 1994;15(Suppl):s143–7. https://doi.org/10.1016/0098-2997(94)90023-x.CrossRefPubMed

31.

•• Alehagen U, Johansson P, Björnstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013;167:1860–6. https://doi.org/10.1016/j.ijcard.2012.04.156. Proving that CoQ10 decreases mortality in patients with heart failure after 5 years.CrossRefPubMed

32.

Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10 years after supplementation with selenium and Coenzyme Q10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens. PLoS ONE. 2015;10:e0141641. https://doi.org/10.1371/journal.pone.0141641.CrossRefPubMedPubMedCentral

33.

Alehagen U, Lindahl TL, Aaseth J, et al. Levels of sP-selectin and hs-CRP Decrease with dietary intervention with selenium and Coenzyme Q10 combined: a secondary analysis of a randomized clinical trial. PLoS ONE. 2015;10:e0137680. https://doi.org/10.1371/journal.pone.0137680.CrossRefPubMedPubMedCentral

34.

Alehagen U, Alexander J, Aaseth J. Supplementation with selenium and Coenzyme Q10 reduces cardiovascular mortality in elderly with low selenium status. a secondary analysis of a randomised clinical trial. PLoS One 2016;11:e0157541. https://doi.org/10.1371/journal.pone.0157541.

35.

Alehagen U, Aaseth J, Alexander J, et al. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: a validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. PLoS ONE. 2018;13:e0193120. https://doi.org/10.1371/journal.pone.0193120.CrossRefPubMedPubMedCentral

36.

Alehagen U, Aaseth J, Lindahl TL, et al. (2021) Dietary supplementation with selenium and Coenzyme Q10 prevents increase in plasma D-dimer while lowering cardiovascular mortality in an elderly Swedish population. Nutrients 2021;13. https://doi.org/10.3390/nu13041344.

37.

Opstad TB, Alexander J, Aaseth JO, et al. Selenium and Coenzyme Q10 intervention prevents telomere attrition, with association to reduced cardiovascular mortality-sub-study of a randomized clinical trial. Nutrients 2022;14. https://doi.org/10.3390/nu14163346.

38.

Alehagen U, Johansson P, Svensson E, et al. Improved cardiovascular health by supplementation with selenium and coenzyme Q10: applying structural equation modelling (SEM) to clinical outcomes and biomarkers to explore underlying mechanisms in a prospective randomized double-blind placebo-controlled intervention project in Sweden. Eur J Nutr. 2022;61:3135–48. https://doi.org/10.1007/s00394-022-02876-1.CrossRefPubMedPubMedCentral

39.

Orlando P, Sabbatinelli J, Silvestri S, et al. Ubiquinol supplementation in elderly patients undergoing aortic valve replacement: biochemical and clinical aspects. Aging (Albany NY) 2020;12:15514–15531. https://doi.org/10.18632/aging.103742.

40.

Kawashima C, Matsuzawa Y, Konishi M, et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. Am J Cardiovasc Drugs. 2020;20:363–72. https://doi.org/10.1007/s40256-019-00384-y.CrossRefPubMed

41.

Holmberg MJ, Andersen LW, Moskowitz A, et al. Ubiquinol (reduced coenzyme Q10) as a metabolic resuscitator in post-cardiac arrest: a randomized, double-blind, placebo-controlled trial. Resuscitation. 2021;162:388–95. https://doi.org/10.1016/j.resuscitation.2021.01.041.CrossRefPubMed

42.

Samuel TY, Hasin T, Gotsman I, et al. Coenzyme Q10 in the treatment of heart failure with preserved ejection fraction: a prospective, randomized, double-blind, placebo-controlled trial. Drugs R D. 2022;22:25–33. https://doi.org/10.1007/s40268-021-00372-1.CrossRefPubMed

43.

• Pierce JD, Shen Q, Mahoney DE, et al. Effects of ubiquinol and/or D-ribose in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2022;176:79–88. https://doi.org/10.1016/j.amjcard.2022.04.031. Showing that higher concentrations of CoQH2 are needed to reach any effect.CrossRefPubMedPubMedCentral

44.

Caso G, Kelly P, McNurlan MA, et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409–12. https://doi.org/10.1016/j.amjcard.2006.12.063.CrossRefPubMed

45.

Derosa G, D’Angelo A, Maffioli P. Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. Drug Des Devel Ther. 2019;13:3647–55. https://doi.org/10.2147/DDDT.S223153.CrossRefPubMedPubMedCentral

46.

Skarlovnik A, Janić M, Lunder M, et al. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit 2014;20:2183–2188. https://doi.org/10.12659/MSM.890777.

47.

Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig. 1993;71:S60–5. https://doi.org/10.1007/BF00226842.CrossRefPubMed

48.

Niki E. Mechanisms and dynamics of antioxidant action of ubiquinol. Mol Aspects Med. 1997;18(Suppl):S63-70. https://doi.org/10.1016/S0098-2997(97)00035-6.CrossRefPubMed

49.

Judy WV. Coenzyme Q10: an insider’s guide. 2018.

50.

Wang TY, Liu M, Portincasa P, et al. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest. 2013;43:1203–23. https://doi.org/10.1111/eci.12161.CrossRefPubMedPubMedCentral

Title: Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality
Authors: Johannes-Paul Fladerer
Selina Grollitsch
Publication date: 16-11-2023
Publisher: Springer US
Keyword: Heart Failure
Published in: Current Cardiology Reports / Issue 12/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01992-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2023

Screening for Coronary Artery Disease in Patients with Diabetes

Multi-proteomic Biomarker Risk Scores for Predicting Risk and Guiding Therapy in Patients with Coronary Artery Disease

Antibiotic prophylaxis for infective endocarditis

The Role of Artificial Intelligence in Echocardiography: A Clinical Update

Achieving Health Equity in the Care of Patients with Heart Failure

Using Technology to Deliver Cardiovascular Care in African Countries

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page